Head-to-head
BPC-157 vs Semaglutide
A field-by-field comparison of BPC-157 and Semaglutide drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. They belong to different categories — recovery & repair and metabolic — so this page focuses on what each one actually does rather than which is "better".
BPC-157 vs Semaglutide at a glance
| Attribute | BPC-157 | Semaglutide |
|---|---|---|
| Category | Recovery & repair | Metabolic |
| Evidence grade | Emerging | Strong |
| Also known as | Body Protection Compound 157, PL 14736 | Ozempic, Wegovy |
| Chain | 15 amino acids (GEPPPGKPADDAGLV) | GLP-1 analogue, 94% homology to human GLP-1 |
| Mechanism | Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining. | Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing. |
| Reported benefits | Faster tendon, ligament and muscle healing in rodent models · Protective effect on the gastrointestinal lining, including NSAID-induced damage · Reduced local inflammation around injury sites · Anecdotal relief from tendinopathy and joint pain | ~15% mean body-weight reduction over 68 weeks in STEP-1 · Improved HbA1c and cardiovascular outcomes · Marked reduction in appetite and food noise |
| Reported side effects | Injection-site irritation · Transient dizziness or nausea · Unknown long-term safety profile | Nausea and vomiting · Constipation or diarrhoea · Gallbladder issues · Contraindicated with medullary thyroid carcinoma history |
| Half-life | Approximately 4 hours (stable oral form debated) | About 7 days |
| Administration | Subcutaneous injection; oral capsules used for gut-specific goals | Once-weekly subcutaneous injection (oral tablet also approved) |
| Dosing overview | Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks | Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks |
| Storage | Lyophilised powder refrigerated; reconstituted vials 2–8 °C, used within ~30 days | Refrigerate 2–8 °C; in-use pens may be kept at room temperature per label |
| Legal status | Not FDA-approved. Research-chemical status in most countries; prohibited in sport. | FDA-approved and prescription-only. |
Key differences between BPC-157 and Semaglutide
Different categories, different goals
BPC-157 is indexed under recovery & repair, while Semaglutide sits under metabolic. They are not substitutes for one another: BPC-157 is described as "A synthetic fragment of a protein found in gastric juice, widely used in the recovery community for tendon, gut and soft-tissue complaints." and Semaglutide as "A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market."
Mechanism of action
BPC-157: Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining. Semaglutide: Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing.
Evidence quality is not equal
BPC-157 carries a Emerging evidence grade and Semaglutide a Strong grade on this index. The grade describes the quality of published human data, not how well a compound works — Semaglutide has the better-documented record of the two, and claims made about BPC-157 rest on thinner human evidence.
Half-life and dosing frequency
BPC-157 is listed at approximately 4 hours (stable oral form debated); Semaglutide at about 7 days. That difference is what drives the reported schedules: Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks versus Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks
Route of administration
BPC-157 is administered by subcutaneous injection; oral capsules used for gut-specific goals. Semaglutide is administered by once-weekly subcutaneous injection (oral tablet also approved).
Legal and regulatory status differs
BPC-157: Not FDA-approved. Research-chemical status in most countries; prohibited in sport. Semaglutide: FDA-approved and prescription-only. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
BPC-157 is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c, used within ~30 days. Semaglutide is stored refrigerate 2–8 °c; in-use pens may be kept at room temperature per label.
What BPC-157 and Semaglutide have in common
On the attributes tracked in this database — category, evidence grade, mechanism, half-life, administration, dosing overview, storage and legal status — BPC-157 and Semaglutide share no identical values. They are compared here because they come up together in the same searches, not because they overlap.
Each compound in brief
BPC-157
Recovery & repair · Emerging evidence
A synthetic fragment of a protein found in gastric juice, widely used in the recovery community for tendon, gut and soft-tissue complaints.
Considerations: Nearly all evidence is preclinical (rodent); robust human trials are absent · Injected near the injury site is the common anecdotal practice, though systemic effects are proposed · Banned by WADA for competing athletes
Semaglutide
Metabolic · Strong evidence
A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market.
Considerations: Muscle loss can account for a meaningful share of weight lost — resistance training and protein intake matter · GI side effects are dose-dependent; titrate slowly · Weight regain is common after stopping
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.